Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study

Saito, Takuro; Kurokawa, Yukinori; Fujitani, Kazumasa; Kawabata, Ryohei; Takeno, Atsushi; Mikami, Jota; Endo, Shunji; Matsuyama, Jin; Akamaru, Yusuke; Hirota, Masashi; Kishi, Kentaro; Urakawa, Shinya; Yamamoto, Kei; Tanaka, Koji; Takahashi, Tsuyoshi; Oka, Mikio; Wada, Hisashi; Eguchi, Hidetoshi; Doki, Yuichiro

doi:https://doi.org/10.1038/s41416-023-02540-3

Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study

Saito, Takuro; Kurokawa, Yukinori; Fujitani, Kazumasa et al.

British Journal of Cancer, 2024, 130, 1157-1165

Number of Access:2,362（2025-08-15 06:45 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/94644

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
BrJCancer_41416-023-02540-3	pdf	None	766 KB	74	2024.03.13

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study
Creator	NRID 1000020646468 1000020646468 researchmap permalink tsaito19 tsaito19 Scopus Author ID 57211629912 57211629912 CreatorName Saito, Takuro
	NRID 1000010470197 1000010470197 researchmap permalink krkw krkw Scopus Author ID 7202562410 7202562410 CreatorName Kurokawa, Yukinori
	CreatorName Fujitani, Kazumasa
	CreatorName Kawabata, Ryohei
	CreatorName Takeno, Atsushi
	CreatorName Mikami, Jota
	CreatorName Endo, Shunji
	CreatorName Matsuyama, Jin
	CreatorName Akamaru, Yusuke
	CreatorName Hirota, Masashi
	CreatorName Kishi, Kentaro
	NRID 1000040768975 1000040768975 researchmap permalink surakawa-surakawa surakawa-surakawa CreatorName Urakawa, Shinya
	NRID 1000090835240 1000090835240 CreatorName Yamamoto, Kei
	NRID 1000070621019 1000070621019 ORCID 0000-0001-5178-9388 0000-0001-5178-9388 researchmap permalink koji_tanaka koji_tanaka Scopus Author ID 55628548952 55628548952 CreatorName Tanaka, Koji
	NRID 1000050452389 1000050452389 ORCID 0000-0003-2397-1478 0000-0003-2397-1478 researchmap permalink mihogaoka13611 mihogaoka13611 Scopus Author ID 56182761100 56182761100 CreatorName Takahashi, Tsuyoshi
	NRID 1000040223995 1000040223995 CreatorName Oka, Mikio
	NRID 1000070243459 1000070243459 researchmap permalink hwada hwada Scopus Author ID 7402917501 7402917501 CreatorName Wada, Hisashi
	NRID 1000090542118 1000090542118 researchmap permalink abcdabcdabcd abcdabcdabcd Scopus Author ID 7101627772 7101627772 CreatorName Eguchi, Hidetoshi
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 CreatorName Doki, Yuichiro
Description	The version of record of this article, first published in British Journal of Cancer, is available online at Publisher’s website: https://doi.org/10.1038/s41416-023-02540-3
Abstract	Background: No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer. Methods: A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively. Results: Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively). p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months (P < 0.03) and 12 months (P < 0.001) were independent prognostic factors for a shorter recurrence-free interval. Conclusions: Serum NY-ESO-1 antibodies may be a useful predictive marker for postoperative recurrence in gastric cancer. Clinical trial registration: UMIN000007925.
Publisher	Springer Nature
Source Title	British Journal of Cancer
Volume (Issue)	130
Page	1157-1165
Date of Issued	2024-02-07
Language	English
Handle URL	https://hdl.handle.net/11094/94644
PISSN	00070920
eISSN	15321827
Relation
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1038/s41416-023-02540-3
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	British Journal of Cancer. 2024, 130, p. 1157-1165
DC.title	Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study
DC.creator	Saito, Takuro
	Kurokawa, Yukinori
	Fujitani, Kazumasa
	Kawabata, Ryohei
	Takeno, Atsushi
	Mikami, Jota
	Endo, Shunji
	Matsuyama, Jin
	Akamaru, Yusuke
	Hirota, Masashi
	Kishi, Kentaro
	Urakawa, Shinya
	Yamamoto, Kei
	Tanaka, Koji
	Takahashi, Tsuyoshi
	Oka, Mikio
	Wada, Hisashi
	Eguchi, Hidetoshi
	Doki, Yuichiro
DC.publisher	Springer Nature
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-02-07
DC.identifier	https://doi.org/10.1038/s41416-023-02540-3
DC.description	The version of record of this article, first published in British Journal of Cancer, is available online at Publisher’s website: https://doi.org/10.1038/s41416-023-02540-3
DCTERMS.abstract	Background: No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer. Methods: A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively. Results: Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively). p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months (P < 0.03) and 12 months (P < 0.001) were independent prognostic factors for a shorter recurrence-free interval. Conclusions: Serum NY-ESO-1 antibodies may be a useful predictive marker for postoperative recurrence in gastric cancer. Clinical trial registration: UMIN000007925.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	94644
citation_title	Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study
citation_author	Saito, Takuro
	Kurokawa, Yukinori
	Fujitani, Kazumasa
	Kawabata, Ryohei
	Takeno, Atsushi
	Mikami, Jota
	Endo, Shunji
	Matsuyama, Jin
	Akamaru, Yusuke
	Hirota, Masashi
	Kishi, Kentaro
	Urakawa, Shinya
	Yamamoto, Kei
	Tanaka, Koji
	Takahashi, Tsuyoshi
	Oka, Mikio
	Wada, Hisashi
	Eguchi, Hidetoshi
	Doki, Yuichiro
citation_publisher	Springer Nature
citation_language	English
citation_date	2024-02-07
citation_journal_title	British Journal of Cancer
citation_volume	130
citation_firstpage	1157
citation_lastpage	1165
citation_doi	https://doi.org/10.1038/s41416-023-02540-3
citation_public_url	https://hdl.handle.net/11094/94644

Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study

Link to primary information

Item Information

Show details